Minaris Cell Therapies provides integrated CDMO services to help advance autologous and allogeneic cell therapy programs from process development through GMP manufacturing, testing, release, and commercialization. With 25+ years of cell therapy experience, 7,500+ clinical and commercial GMP batches produced, and commercially experienced sites across three continents, Minaris supports complex modalities including gene-modified and non-gene-modified therapies, T cells, NK cells, B cells, TILs, dendritic cells, Tregs, stem cell therapies, and iPSC-based products. Our globally harmonized quality systems, in-house QC release testing, digital tracking, and clinical-to-commercial GMP infrastructure help reduce handoffs, improve timeline visibility, and support reliable execution from development to patient delivery.
Download the flyer to learn how Minaris Cell Therapies can support your program with integrated development, manufacturing, testing, and release capabilities designed to accelerate the path to clinical and commercial supply.
